ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.31
-2.29%
US Tech 100
20,711.60
-3.36%
S&P 500
5,872.16
-2.95%
US Dollar vs CAD
1.44379
-0.17%
Bitcoin
101,192.86
1.13%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Windtree Therapeutics Inc (WINT)

  7. Windtree Therapeutics Inc (WINT) News

WINT

Windtree Therapeutics (WINT)

Windtree Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:WINT
DateTimeSourceHeadlineSymbolCompany
12/16/20247:00AMGlobeNewswire Inc.Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials ConferenceNASDAQ:WINTWindtree Therapeutics Inc
12/09/20247:00AMGlobeNewswire Inc.Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaNASDAQ:WINTWindtree Therapeutics Inc
12/05/20246:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
12/04/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
12/04/20247:00AMGlobeNewswire Inc.Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic TransactionNASDAQ:WINTWindtree Therapeutics Inc
11/27/20243:43PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
11/27/20243:05PMGlobeNewswire Inc.Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business UpdatesNASDAQ:WINTWindtree Therapeutics Inc
11/14/20247:53AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:WINTWindtree Therapeutics Inc
11/14/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
11/14/20247:00AMGlobeNewswire Inc.Windtree Announces Leadership Transition Plan With Industry VeteransNASDAQ:WINTWindtree Therapeutics Inc
11/04/20247:00AMGlobeNewswire Inc.Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong KongNASDAQ:WINTWindtree Therapeutics Inc
10/30/20247:00AMGlobeNewswire Inc.Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3NASDAQ:WINTWindtree Therapeutics Inc
10/23/20247:00AMGlobeNewswire Inc.Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the WorldNASDAQ:WINTWindtree Therapeutics Inc
10/21/20247:00AMGlobeNewswire Inc.Windtree To Present at the ThinkEquity Conference on October 30thNASDAQ:WINTWindtree Therapeutics Inc
10/17/20247:15AMGlobeNewswire Inc.Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for JapanNASDAQ:WINTWindtree Therapeutics Inc
10/09/20247:00AMGlobeNewswire Inc.Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial DesignNASDAQ:WINTWindtree Therapeutics Inc
10/09/20246:46AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WINTWindtree Therapeutics Inc
09/30/20247:15AMGlobeNewswire Inc.Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
09/26/20243:05PMGlobeNewswire Inc.Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ETNASDAQ:WINTWindtree Therapeutics Inc
09/25/20247:15AMGlobeNewswire Inc.Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
09/25/20247:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
09/24/20244:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
09/04/20247:00AMGlobeNewswire Inc.Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
09/03/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:WINTWindtree Therapeutics Inc
09/03/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:WINTWindtree Therapeutics Inc
09/03/20248:10AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
09/03/20248:09AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
09/03/20246:26AMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:WINTWindtree Therapeutics Inc
09/03/20246:22AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:WINTWindtree Therapeutics Inc
08/23/20243:15PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:WINTWindtree Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:WINT

Your Recent History

NASDAQ
NUKK
Nukkleus
AMEX
KULR
KULR Technology
USOTC
ICTY
Eyecity Com (PK)
AMEX
SPY
SPDR S&P 500
USOTC
VPLM
Voip Pal Com (QB)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
RDAR
Raadr (PK)
NASDAQ
RNAZ
TransCode Therapeutics
USOTC
RDGL
Vivos (QB)
USOTC
SPZI
Spooz (PK)
USOTC
CEOS
CeCors (PK)
NASDAQ
NVDA
NVIDIA
USOTC
AXXA
Exxe (PK)
NASDAQ
NXPL
NextPlat
NASDAQ
COOP
Mr Cooper
NASDAQ
TNXP
Tonix Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved